Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.
Humans
Respiratory Syncytial Virus Infections
/ epidemiology
Germany
/ epidemiology
Hospitalization
/ statistics & numerical data
Cost of Illness
Respiratory Syncytial Virus, Human
/ isolation & purification
Seasons
Infant
Incidence
Child
Health Care Costs
/ statistics & numerical data
Aged
Intensive Care Units
/ statistics & numerical data
Child, Preschool
Adult
Bronchiolitis
Disease burden
Germany
Resource use and costs
Respiratory infection
Respiratory syncytial virus
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
18
12
2023
accepted:
14
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection and hospitalizations among infants, young children, and the elderly. This systematic literature review aimed to summarize the epidemiological and economic burden estimates of RSV infection at any age in Germany. We conducted a systematic literature search to identify full-text articles published from 2003 to 2023 and reporting data on the epidemiological or economic burden of RSV in Germany. Based on pre-specified eligibility criteria, data on incidence, rates of hospital and intensive care unit (ICU) admission, clinical manifestation, underlying conditions, seasonality, health care resource use and costs were extracted. After screening 315 full-text articles, we included 42 articles in the review. The characteristics of the included studies were heterogenous regarding study population, setting, age groups and RSV-related outcome measures. The most frequently reported epidemiological outcome measures were RSV detection rate (n = 33), followed by clinical manifestation (n = 19), seasonality (n = 18), and underlying conditions of RSV infection (n = 13). RSV detection rates were reported across heterogenous study populations, ranging from 5.2 to 55.4% in pediatric inpatient cases and from 2.9 to 14% in adult inpatient cases. All articles that reported RSV detection rates across several age groups demonstrated the highest burden in infants and young children. Few articles reported RSV-related outcome measures distinctively for the outpatient setting. Health care resource use, such as hospital length of stay, ICU admission rate and treatment of patients with RSV infection were described in 23 articles, of which only one study quantified associated costs from 1999 to 2003 for children ≤ 3 years. In-hospital ICU admission rates varied between 3.6 and 45%, depending on population characteristics as age and underlying conditions. This systematic review revealed that RSV imposes substantial disease burden in infants, young children, and the elderly in Germany, whereby infants are particularly affected. To date, there has been limited exploration of the impact of RSV infection on healthy children or the elderly in Germany. Given their notably high reported burden in studies, the medical and economic RSV burden in these groups should move more into focus.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection and hospitalizations among infants, young children, and the elderly. This systematic literature review aimed to summarize the epidemiological and economic burden estimates of RSV infection at any age in Germany.
METHODS
METHODS
We conducted a systematic literature search to identify full-text articles published from 2003 to 2023 and reporting data on the epidemiological or economic burden of RSV in Germany. Based on pre-specified eligibility criteria, data on incidence, rates of hospital and intensive care unit (ICU) admission, clinical manifestation, underlying conditions, seasonality, health care resource use and costs were extracted.
RESULTS
RESULTS
After screening 315 full-text articles, we included 42 articles in the review. The characteristics of the included studies were heterogenous regarding study population, setting, age groups and RSV-related outcome measures. The most frequently reported epidemiological outcome measures were RSV detection rate (n = 33), followed by clinical manifestation (n = 19), seasonality (n = 18), and underlying conditions of RSV infection (n = 13). RSV detection rates were reported across heterogenous study populations, ranging from 5.2 to 55.4% in pediatric inpatient cases and from 2.9 to 14% in adult inpatient cases. All articles that reported RSV detection rates across several age groups demonstrated the highest burden in infants and young children. Few articles reported RSV-related outcome measures distinctively for the outpatient setting. Health care resource use, such as hospital length of stay, ICU admission rate and treatment of patients with RSV infection were described in 23 articles, of which only one study quantified associated costs from 1999 to 2003 for children ≤ 3 years. In-hospital ICU admission rates varied between 3.6 and 45%, depending on population characteristics as age and underlying conditions.
CONCLUSIONS
CONCLUSIONS
This systematic review revealed that RSV imposes substantial disease burden in infants, young children, and the elderly in Germany, whereby infants are particularly affected. To date, there has been limited exploration of the impact of RSV infection on healthy children or the elderly in Germany. Given their notably high reported burden in studies, the medical and economic RSV burden in these groups should move more into focus.
Identifiants
pubmed: 39164625
doi: 10.1186/s12879-024-09758-3
pii: 10.1186/s12879-024-09758-3
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
844Informations de copyright
© 2024. The Author(s).
Références
Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. https://doi.org/10.1016/S0140-6736(17)30938-8 .
doi: 10.1016/S0140-6736(17)30938-8
pubmed: 28689664
pmcid: 5592248
Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. Influenza Other Respir Viruses. 2021;15(6):732–41. https://doi.org/10.1111/irv.12885 .
doi: 10.1111/irv.12885
pubmed: 34255934
pmcid: 8542954
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. https://doi.org/10.1016/S0140-6736(22)00478-0 .
doi: 10.1016/S0140-6736(22)00478-0
pubmed: 35598608
pmcid: 7613574
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodriguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Infect Dis. 2018;217(9):1356–64. https://doi.org/10.1093/infdis/jiy056 .
doi: 10.1093/infdis/jiy056
pubmed: 29390105
Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, et al. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. https://doi.org/10.1186/s12879-021-06399-8 .
doi: 10.1186/s12879-021-06399-8
pubmed: 34340679
pmcid: 8327424
Duan Y, Jiang M, Huang Q, Jia M, Yang W, Feng L. Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus-related diseases: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2023;17(5):e13145. https://doi.org/10.1111/irv.13145 .
doi: 10.1111/irv.13145
pubmed: 37223668
pmcid: 10201211
Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Vazquez Fernandez L, Teirlinck AC, et al. Defining the Burden of Disease of RSV in the European Union: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. J Infect Dis. 2023. https://doi.org/10.1093/infdis/jiad188 .
doi: 10.1093/infdis/jiad188
pubmed: 37246742
pmcid: 10681866
Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western Countries. Infect Dis Ther. 2016;5(3):271–98. https://doi.org/10.1007/s40121-016-0123-0 .
doi: 10.1007/s40121-016-0123-0
pubmed: 27480325
pmcid: 5019979
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6. https://doi.org/10.1001/archpedi.1986.02140200053026 .
doi: 10.1001/archpedi.1986.02140200053026
pubmed: 3706232
Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62–72. https://doi.org/10.1056/NEJMra1413456 .
doi: 10.1056/NEJMra1413456
pubmed: 26735994
Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global Disease Burden estimates of respiratory Syncytial Virus-Associated Acute respiratory infection in older adults in 2015: a systematic review and Meta-analysis. J Infect Dis. 2020;222(Suppl 7):S577–83. https://doi.org/10.1093/infdis/jiz059 .
doi: 10.1093/infdis/jiz059
pubmed: 30880339
Baraldi E, Bonadies L, Manzoni P. Evidence on the link between respiratory syncytial virus infection in Early Life and Chronic Obstructive Lung diseases. Am J Perinatol. 2020;37(S 02):S26–30. https://doi.org/10.1055/s-0040-1714345 .
doi: 10.1055/s-0040-1714345
pubmed: 32772357
Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137–41. https://doi.org/10.1164/rccm.200406-730OC .
doi: 10.1164/rccm.200406-730OC
pubmed: 15516534
CDC. RSV in Older Adults and Adults with Chronic Medical Conditions. https://www.cdc.gov/rsv/high-risk/older-adults.html Accessed 26 October 2023.
Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality Associated with respiratory Syncytial Virus Versus Influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197–203. https://doi.org/10.1093/cid/ciy991 .
doi: 10.1093/cid/ciy991
pubmed: 30452608
Krilov LR, Roberts NJ. Jr. Respiratory syncytial virus (RSV) update. Viruses. 2022;14(10). https://doi.org/10.3390/v14102110 .
Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020b;14(6):658–70. https://doi.org/10.1111/irv.12729 .
doi: 10.1111/irv.12729
pubmed: 32064773
pmcid: 7578333
Shmueli E, Goldberg O, Mei-Zahav M, Stafler P, Bar-On O, Levine H, et al. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases. Pediatr Pulmonol. 2021;56(7):2204–11. https://doi.org/10.1002/ppul.25435 .
doi: 10.1002/ppul.25435
pubmed: 33913611
Hartmann K, Liese JG, Kemmling D, Prifert C, Weissbrich B, Thilakarathne P, et al. Clinical burden of respiratory Syncytial Virus in Hospitalized Children aged =5 years (INSPIRE study)</at. J Infect Dis. 2022;226(3):386–95. https://doi.org/10.1093/infdis/jiac137 .
doi: 10.1093/infdis/jiac137
pubmed: 35417015
pmcid: 9417125
Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated hospitalizations among children aged < 2 years in the United States, 2014-15. J Pediatr Infect Dis Soc. 2020;9(5):587–95. https://doi.org/10.1093/jpids/piz087 .
doi: 10.1093/jpids/piz087
Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, et al. Respiratory Syncytial Virus-Associated hospitalizations among Young children: 2015–2016. Pediatrics. 2020;146(1). https://doi.org/10.1542/peds.2019-3611 .
Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol. 2001;128(1):23–31. https://doi.org/10.1016/s0034-5687(01)00261-4 .
doi: 10.1016/s0034-5687(01)00261-4
pubmed: 11535259
pmcid: 7130717
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59. https://doi.org/10.1056/NEJMoa043951 .
doi: 10.1056/NEJMoa043951
pubmed: 15858184
Messina A, Germano C, Avellis V, Tavella E, Dodaro V, Massaro A, et al. New strategies for the prevention of respiratory syncytial virus (RSV). Early Hum Dev. 2022;174:105666. https://doi.org/10.1016/j.earlhumdev.2022.105666 .
doi: 10.1016/j.earlhumdev.2022.105666
pubmed: 36174288
Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2–21. https://doi.org/10.1016/S1473-3099(22)00291-2 .
doi: 10.1016/S1473-3099(22)00291-2
pubmed: 35952703
European Medicines Agency. Synagis - palivizumab. Annex I - Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_en.pdf . Accessed 22 July 2024.
Gemeinsamer Bundesausschuss. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Anlage 4: Therapiehinweis zu Palivizumab [BAnz. Nr. 181 (S. 4 260) vom 27.11.2008]. https://www.g-ba.de/downloads/39-261-694/2008-06-19-AMR4-Palivizumab_BAnz.pdf . Accessed 22 July 2024.
Buda S, Preuß U. Robert Koch-Institut. Bericht zur Epidemiologie der Influenza in Deutschland, Saison 2018/19, Berlin. 2019. https://doi.org/10.25646/6232
Robert Koch-Institut. FAQ-Liste zu RSV-Infektionen. https://www.rki.de/SharedDocs/FAQ/RSV/FAQ_Liste_RSV.html . Accessed 26 October 2023.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535 .
doi: 10.1136/bmj.b2535
pubmed: 19622551
pmcid: 2714657
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. https://doi.org/10.1371/journal.pmed.1003583 .
doi: 10.1371/journal.pmed.1003583
pubmed: 33780438
pmcid: 8007028
Weigl JA, Puppe W, Schmitt HJ. Can respiratory syncytial virus etiology be diagnosed clinically? A hospital-based case-control study in children under two years of age. Eur J Epidemiol. 2003;18(5):431–9. https://doi.org/10.1023/a:1024213400297 .
doi: 10.1023/a:1024213400297
pubmed: 12889690
Tabatabai J, Ihling CM, Rehbein RM, Schnee SV, Hoos J, Pfeil J, et al. Molecular epidemiology of respiratory syncytial virus in hospitalised children in Heidelberg, Southern Germany, 2014–2017. Infect Genet Evol. 2022;98:105209. https://doi.org/10.1016/j.meegid.2022.105209 .
doi: 10.1016/j.meegid.2022.105209
pubmed: 35032683
Tabatabai J, Ihling CM, Manuel B, Rehbein RM, Schnee SV, Hoos J, et al. Viral etiology and clinical characteristics of Acute Respiratory Tract infections in Hospitalized Children in Southern Germany (2014–2018). Open Forum Infect Dis. 2023;10(3):ofad110. https://doi.org/10.1093/ofid/ofad110 .
doi: 10.1093/ofid/ofad110
pubmed: 36968956
pmcid: 10034757
Weigl JA, Puppe W, Schmitt HJ. Variables explaining the duration of hospitalization in children under two years of age admitted with acute airway infections: does respiratory syncytial virus have a direct impact? Klin Padiatr. 2004;216(1):7–15. https://doi.org/10.1055/s-2004-817688 .
doi: 10.1055/s-2004-817688
pubmed: 14747964
An der Heiden M, Buchholz U, Buda S. Estimation of influenza- and respiratory syncytial virus-attributable medically attended acute respiratory infections in Germany, 2010/11-2017/18. Influenza Other Respir Viruses. 2019;13(5):517–21. https://doi.org/10.1111/irv.12666 .
doi: 10.1111/irv.12666
pubmed: 31339223
pmcid: 6692544
Bierbaum S, Forster J, Berner R, Rucker G, Rohde G, Neumann-Haefelin D, et al. Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10. Arch Virol. 2014;159(4):669–76. https://doi.org/10.1007/s00705-013-1876-3 .
doi: 10.1007/s00705-013-1876-3
pubmed: 24126621
Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020a;14(6):630–7. https://doi.org/10.1111/irv.12665 .
doi: 10.1111/irv.12665
pubmed: 31206246
Cai W, Durrwald R, Biere B, Schweiger B, Haas W, Wolff T, et al. Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany. Influenza Other Respir Viruses. 2022;16(5):854–7. https://doi.org/10.1111/irv.12996 .
doi: 10.1111/irv.12996
pubmed: 35485999
pmcid: 9343324
Ehlken B, Ihorst G, Lippert B, Rohwedder A, Petersen G, Schumacher M, et al. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr. 2005;164(10):607–15. https://doi.org/10.1007/s00431-005-1705-0 .
doi: 10.1007/s00431-005-1705-0
pubmed: 15965766
Forster J. Influenza in children: the German perspective. Pediatr Infect Dis J. 2003;22(10 Suppl):S215-7. https://doi.org/10.1097/01.inf.0000092190.43140.f7 .
doi: 10.1097/01.inf.0000092190.43140.f7
pubmed: 14551478
Forster J, Ihorst G, Rieger CH, Stephan V, Frank HD, Gurth H, et al. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur J Pediatr. 2004;163(12):709–16. https://doi.org/10.1007/s00431-004-1523-9 .
doi: 10.1007/s00431-004-1523-9
pubmed: 15372233
Gröndahl B, Ankermann T, von Bismarck P, Rockahr S, Kowalzik F, Gehring S, et al. The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children. Infection. 2014;42(2):303–8. https://doi.org/10.1007/s15010-013-0545-5 .
doi: 10.1007/s15010-013-0545-5
pubmed: 24150959
Kiefer A, Pemmerl S, Kabesch M, Ambrosch A. Comparative analysis of RSV-related hospitalisations in children and adults over a 7 year-period before, during and after the COVID-19 pandemic. J Clin Virol. 2023;166:105530. https://doi.org/10.1016/j.jcv.2023.105530 .
doi: 10.1016/j.jcv.2023.105530
pubmed: 37481874
Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, et al. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162(4):230–6. https://doi.org/10.1007/s00431-002-1105-7 .
doi: 10.1007/s00431-002-1105-7
pubmed: 12647195
Reiche J, Schweiger B. Genetic variability of group a human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. J Clin Microbiol. 2009;47(6):1800–10. https://doi.org/10.1128/JCM.02286-08 .
doi: 10.1128/JCM.02286-08
pubmed: 19386848
pmcid: 2691087
Simon A, Ammann RA, Wilkesmann A, Eis-Hubinger AM, Schildgen O, Weimann E, et al. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007;166(12):1273–83. https://doi.org/10.1007/s00431-007-0426-y .
doi: 10.1007/s00431-007-0426-y
pubmed: 17943313
Simon A, Muller A, Khurana K, Engelhart S, Exner M, Schildgen O, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection–results from a prospective multicenter German surveillance study. Int J Hyg Environ Health. 2008;211(3–4):241–50. https://doi.org/10.1016/j.ijheh.2007.07.020 .
doi: 10.1016/j.ijheh.2007.07.020
pubmed: 17869579
Simon A, Nowak H, Sterz R. Use of palivizumab in Germany: data from 2002–2007. Klin Padiatr. 2011;223(5):292–8. https://doi.org/10.1055/s-0030-1270515 .
doi: 10.1055/s-0030-1270515
pubmed: 21509705
Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S. Use of Palivizumab in Germany - Report from the German Synagis Registry 2009–2016. Klin Padiatr. 2018a;230(5):263–9. https://doi.org/10.1055/a-0595-7771 .
doi: 10.1055/a-0595-7771
pubmed: 29660756
Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S. Risk factors and main indications for Palivizumab Prophylaxis in a second season Population: results from the German Synagis Registry 2009–2016. Pediatr Infect Dis J. 2018b;37(10):987–91. https://doi.org/10.1097/INF.0000000000002133 .
doi: 10.1097/INF.0000000000002133
pubmed: 30020201
Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S. Palivizumab use in infants with Down syndrome-report from the German Synagis Registry 2009–2016. Eur J Pediatr. 2018c;177(6):903–11. https://doi.org/10.1007/s00431-018-3142-x .
doi: 10.1007/s00431-018-3142-x
pubmed: 29651734
Streng A, Goettler D, Haerlein M, Lehmann L, Ulrich K, Prifert C, et al. Spread and clinical severity of respiratory syncytial virus a genotype ON1 in Germany, 2011–2017. BMC Infect Dis. 2019;19(1):613. https://doi.org/10.1186/s12879-019-4266-y .
doi: 10.1186/s12879-019-4266-y
pubmed: 31299924
pmcid: 6624929
Tenenbaum T, Doenhardt M, Diffloth N, Berner R, Armann JP. High burden of RSV hospitalizations in Germany 2021–2022. Infection. 2022;50(6):1587–90. https://doi.org/10.1007/s15010-022-01889-6 .
doi: 10.1007/s15010-022-01889-6
pubmed: 35904753
pmcid: 9334552
Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M. Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect Dis. 2005;5:20. https://doi.org/10.1186/1471-2334-5-20 .
doi: 10.1186/1471-2334-5-20
pubmed: 15801975
pmcid: 1084247
Weigl JA, Puppe W, Belke O, Neususs J, Bagci F, Schmitt HJ. Population-based incidence of severe pneumonia in children in Kiel. Ger Klin Padiatr. 2005;217(4):211–9. https://doi.org/10.1055/s-2004-822699 .
doi: 10.1055/s-2004-822699
Weigl JA, Puppe W, Meyer CU, Berner R, Forster J, Schmitt HJ, et al. Ten years’ experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66. https://doi.org/10.1007/s00431-007-0496-x .
doi: 10.1007/s00431-007-0496-x
pubmed: 17569085
pmcid: 7087302
Weinberger R, Riffelmann M, Kennerknecht N, Hulsse C, Littmann M, O’Brien J, et al. Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens. Eur J Clin Microbiol Infect Dis. 2018;37(4):665–72. https://doi.org/10.1007/s10096-017-3158-6 .
doi: 10.1007/s10096-017-3158-6
pubmed: 29302815
pmcid: 7088169
Wetzke M, Schutz K, Kopp MV, Seidenberg J, Vogelberg C, Ankermann T, et al. Pathogen Spectra in hospitalised and nonhospitalised children with community-acquired pneumonia. ERJ Open Res. 2023;9(2). https://doi.org/10.1183/23120541.00286-2022 .
Wilkesmann A, Ammann RA, Schildgen O, Eis-Hubinger AM, Muller A, Seidenberg J, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26(6):485–91. https://doi.org/10.1097/INF.0b013e31805d01e3 .
doi: 10.1097/INF.0b013e31805d01e3
pubmed: 17529864
Alchikh M, Conrad T, Hoppe C, Ma X, Broberg E, Penttinen P, et al. Are we missing respiratory viral infections in infants and children? Comparison of a hospital-based quality management system with standard of care. Clin Microbiol Infect. 2019;25(3):e3809–16. https://doi.org/10.1016/j.cmi.2018.05.023 .
doi: 10.1016/j.cmi.2018.05.023
Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A / B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161:105399. https://doi.org/10.1016/j.jcv.2023.105399 .
doi: 10.1016/j.jcv.2023.105399
pubmed: 36863135
pmcid: 9927795
Hönemann M, Thiem S, Bergs S, Berthold T, Propach C, Siekmeyer M, et al. In-Depth analysis of the re-emergence of respiratory Syncytial Virus at a Tertiary Care Hospital in Germany in the summer of 2021 after the alleviation of non-pharmaceutical interventions due to the SARS-CoV-2 pandemic. Viruses. 2023;15(4). https://doi.org/10.3390/v15040877 .
Maison N, Peck A, Illi S, Meyer-Buehn M, von Mutius E, Hubner J, et al. The rising of old foes: impact of lockdown periods on non-SARS-CoV-2 viral respiratory and gastrointestinal infections. Infection. 2022;50(2):519–24. https://doi.org/10.1007/s15010-022-01756-4 .
doi: 10.1007/s15010-022-01756-4
pubmed: 35076891
pmcid: 8787179
Mentel R, Ilgert U, Wegner U, Zimmerman K, Bruns R, Gurtler L. Molecular and clinical characteristics of respiratory syncytial virus infections in hospitalized children. Med Microbiol Immunol. 2005;194(1–2):67–71. https://doi.org/10.1007/s00430-003-0215-9 .
doi: 10.1007/s00430-003-0215-9
pubmed: 14722763
Meyer M, Ruebsteck E, Eifinger F, Klein F, Oberthuer A, van Koningsbruggen-Rietschel S, et al. Morbidity of respiratory syncytial virus (RSV) infections: RSV compared with severe Acute Respiratory Syndrome Coronavirus 2 infections in children aged 0–4 years in Cologne, Germany. J Infect Dis. 2022;226(12):2050–3. https://doi.org/10.1093/infdis/jiac052 .
doi: 10.1093/infdis/jiac052
pubmed: 35172330
Schreiner D, Groendahl B, Puppe W, Off HNT, Poplawska K, Knuf M, et al. High antibiotic prescription rates in hospitalized children with human metapneumovirus infection in comparison to RSV infection emphasize the value of point-of-care diagnostics. Infection. 2019;47(2):201–7. https://doi.org/10.1007/s15010-018-1194-5 .
doi: 10.1007/s15010-018-1194-5
pubmed: 30132249
Tabatabai J, Prifert C, Pfeil J, Grulich-Henn J, Schnitzler P. Novel respiratory syncytial virus (RSV) genotype ON1 predominates in Germany during winter season 2012-13. PLoS ONE. 2014;9(10):e109191. https://doi.org/10.1371/journal.pone.0109191 .
doi: 10.1371/journal.pone.0109191
pubmed: 25290155
pmcid: 4188618
Topoulos S, Giesa C, Gatermann S, Fussen R, Lemmen S, Ewig S. Analysis of acute respiratory infections due to influenza virus A, B and RSV during an influenza epidemic 2018. Infection. 2019;47(3):425–33. https://doi.org/10.1007/s15010-018-1262-x .
doi: 10.1007/s15010-018-1262-x
pubmed: 30649684
Vogel M, Grund S, Pandey S, Mayatepek E, Schroten H, Tenenbaum T, et al. What we have learned from the Influenza A pH1N1 2009/10 pandemic: high clinical impact of human metapneumovirus and respiratory Syncytial Virus in Hospitalized Pediatric patients. Jpn J Infect Dis. 2016;69(1):6–11. https://doi.org/10.7883/yoken.JJID.2014.424 .
doi: 10.7883/yoken.JJID.2014.424
pubmed: 25971322
Wasem S, Weichert S, Walther S, Weigl JA, Puppe W, Ihorst G, et al. Lower respiratory tract disease in children: constant pathogens - constant management?! Klin Padiatr. 2008;220(5):291–5. https://doi.org/10.1055/s-2007-990301 .
doi: 10.1055/s-2007-990301
pubmed: 18095251
Reeves RM, van Wijhe M, Tong S, Lehtonen T, Stona L, Teirlinck AC, et al. Respiratory Syncytial Virus-Associated Hospital admissions in children younger than 5 years in 7 European Countries using routinely collected datasets. J Infect Dis. 2020;222(Suppl 7):S599–605. https://doi.org/10.1093/infdis/jiaa360 .
doi: 10.1093/infdis/jiaa360
pubmed: 32815542
Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Boas H, et al. Estimation of the number of RSV-associated hospitalisations in adults in the European Union. J Infect Dis. 2023. https://doi.org/10.1093/infdis/jiad189 .
doi: 10.1093/infdis/jiad189
pubmed: 37246742
pmcid: 10681866
Johannesen CK, van Wijhe M, Tong S, Fernandez LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory Syncytial Virus-Associated hospitalizations in 6 European countries: a Time Series Analysis. J Infect Dis. 2022;226(Suppl 1):S29–37. https://doi.org/10.1093/infdis/jiac150 .
doi: 10.1093/infdis/jiac150
pubmed: 35748871
Figueras-Aloy J, Manzoni P, Paes B, Simoes EA, Bont L, Checchia PA, et al. Defining the risk and Associated Morbidity and Mortality of severe respiratory syncytial virus infection among Preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5(4):417–52. https://doi.org/10.1007/s40121-016-0130-1 .
doi: 10.1007/s40121-016-0130-1
pubmed: 27628014
pmcid: 5125133
Hon KL, Leung TF, Cheng WY, Ko NM, Tang WK, Wong WW, et al. Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis. J Crit Care. 2012;27(5):464–8. https://doi.org/10.1016/j.jcrc.2011.12.001 .
doi: 10.1016/j.jcrc.2011.12.001
pubmed: 22227087
Manzoni P, Figueras-Aloy J, Simoes EAF, Checchia PA, Fauroux B, Bont L, et al. Defining the incidence and Associated Morbidity and Mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther. 2017;6(3):383–411. https://doi.org/10.1007/s40121-017-0160-3 .
doi: 10.1007/s40121-017-0160-3
pubmed: 28653300
pmcid: 5595774
Papenburg J, Hamelin ME, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis. 2012;206(2):178–89. https://doi.org/10.1093/infdis/jis333 .
doi: 10.1093/infdis/jis333
pubmed: 22551815
Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019). Infection. 2023. https://doi.org/10.1007/s15010-023-02122-8 .
doi: 10.1007/s15010-023-02122-8
pubmed: 37973718
Brown PM, Schneeberger DL, Piedimonte G. Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev. 2015;16(4):232–40. https://doi.org/10.1016/j.prrv.2015.05.005 .
doi: 10.1016/j.prrv.2015.05.005
pubmed: 26074450
pmcid: 4656140
Fusco F, Hocking L, Stockwell S, Bonsu M, Marjanovic S, et al. The burden of respiratory syncytial virus: understanding impacts on the NHS, society and economy. Rand Health Q. 2022;10(1):2 PMID: 36484078.
pubmed: 36484078
pmcid: 9718057
Surie D, Yuengling KA, DeCuir J, Zhu Y, Gaglani M, Ginde AA, et al. Disease Severity of Respiratory Syncytial Virus compared with COVID-19 and Influenza among hospitalized adults aged >/=60 years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1083–8. https://doi.org/10.15585/mmwr.mm7240a2 .
doi: 10.15585/mmwr.mm7240a2
pubmed: 37796753
pmcid: 10564326
Wick M, Poshtiban A, Kramer R, Bangert M, Lange M, Wetzke M, et al. Inpatient burden of respiratory syncytial virus in children =2 years of age in Germany: a retrospective analysis of nationwide hospitalization data, 2019–2022</at. Influenza Other Respir Viruses. 2023;17(11):e13211. https://doi.org/10.1111/irv.13211 .
doi: 10.1111/irv.13211
pubmed: 38019702
pmcid: 10667831